Berufliche Reintegration in einer neurologischen Phase-II-Einrichtung

M. Spranger

doi:10.5414/prp20193

Berufliche Reintegration in einer neurologischen Phase-II-Einrichtung

Prävention und Rehabilitation ◽

10.5414/prp20193 ◽

2008 ◽

Vol 20 (10) ◽

pp. 193-196

Author(s):

M. Spranger

Keyword(s):

Phase Ii ◽

Berufliche Reintegration

Auswirkungen einer vierwöchigen ambulanten kardialen Rehabilitationsmaßnahme (Phase II) auf kardiovaskuläre Risikofaktoren, körperliche Belastbarkeit und berufliche Reintegration bei Patienten nach Myokardinfarkt, Dilatationsbehandlung und Herzoperation

Herz ◽

10.1007/bf03042131 ◽

1999 ◽

Vol 24 (S1) ◽

pp. 44-56 ◽

Cited By ~ 4

Author(s):

Detlef B. Gysan ◽

Rainer Heinzler ◽

Katrin Schmidt

Keyword(s):

Phase Ii ◽

Kardiovaskuläre Risikofaktoren ◽

Berufliche Reintegration ◽

Körperliche Belastbarkeit

Phase II study of safety, efficacy and pharmacokinetics of BXT-51072 in patients with mild-moderately active ulcerative colitis

Gastroenterology ◽

10.1016/s0016-5085(01)81390-1 ◽

2001 ◽

Vol 120 (5) ◽

pp. A280-A280

Author(s):

S HANAUER ◽

P MINER ◽

A KESHAVARZIAN ◽

E MORRIS ◽

B SALZBERG ◽

...

Keyword(s):

Ulcerative Colitis ◽

Phase Ii ◽

Phase Ii Study ◽

Active Ulcerative Colitis

1400: A Randomized Phase II Trial Evaluating the Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Grafting in Patients Undergoing a Unilateral Cavernous Nerve Sparing Radical Prostatectomy for Clinically localized PR

The Journal of Urology ◽

10.1016/s0022-5347(18)31601-x ◽

2007 ◽

Vol 177 (4S) ◽

pp. 461-461 ◽

Cited By ~ 1

Author(s):

Christopher G. Wood ◽

David Chang ◽

Run Wang ◽

Yu Shen ◽

Curtis A. Pettaway ◽

...

Keyword(s):

Erectile Dysfunction ◽

Radical Prostatectomy ◽

Phase Ii ◽

Sural Nerve ◽

Phase Ii Trial ◽

Nerve Sparing ◽

Nerve Grafting ◽

Cavernous Nerve ◽

Randomized Phase Ii

1142: Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Prior to Radical Prostatectomy for Patients with High Risk Localized Prostate Cancer: Pathologic Outcomes and 3-Year Follow-Up Analyses

The Journal of Urology ◽

10.1016/s0022-5347(18)31356-9 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 377-377

Author(s):

Martin E. Gleave ◽

Kim Chi ◽

Joseph L. Chin ◽

Eric Winquist ◽

Laurence H. Klotz ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Hormone Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Localized Prostate Cancer ◽

Multicenter Phase

1326: Phase II Trial of Gemcitabine, Paclitaxel, and Cisplatin in Advanced Transitional Cell Carcinoma

The Journal of Urology ◽

10.1016/s0022-5347(18)35471-5 ◽

2005 ◽

Vol 173 (4S) ◽

pp. 360-360

Author(s):

Peter E. Clark ◽

Diana Stindt ◽

M. Craig Hall ◽

Michele Harmon ◽

James F. Lovato ◽

...

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Transitional Cell

Experimental Drug Shows Activity Against Advanced Ovarian Cancer in Phase II Trial

Ob Gyn News ◽

10.1016/s0029-7437(07)70576-1 ◽

2007 ◽

Vol 42 (13) ◽

pp. 2

Author(s):

PATRICE WENDLING

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Experimental Drug

CNTO 1275 for Psoriasis Holds Steady in Phase II

Skin & Allergy News ◽

10.1016/s0037-6337(06)71375-4 ◽

2006 ◽

Vol 37 (7) ◽

pp. 28

Author(s):

SHERRY BOSCHERT

Keyword(s):

Phase Ii

Clinical management of patients undergoing biological therapy, with recombinant human interleukin-2 (rhIL-2): Experiences in a phase II study

Clinical Oncology ◽

10.1016/s0936-6555(05)81237-3 ◽

1991 ◽

Vol 3 ◽

pp. 295-295

Keyword(s):

Phase Ii ◽

Clinical Management ◽

Biological Therapy ◽

Phase Ii Study ◽

Interleukin 2

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

Her2 Positive

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study